Predictive Oncology (NASDAQ:POAI) Stock Price Crosses Below 200-Day Moving Average of $3.98

Predictive Oncology Inc. (NASDAQ:POAIGet Free Report)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.98 and traded as low as $3.11. Predictive Oncology shares last traded at $3.11, with a volume of 20,587 shares.

Predictive Oncology Price Performance

The stock has a market cap of $11.62 million, a PE ratio of -0.63 and a beta of 1.57. The company’s fifty day moving average is $3.31 and its 200-day moving average is $3.97.

Insider Activity

In other news, Director Charles Lee Sr Nuzum, Sr. sold 10,000 shares of the business’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $3.04, for a total value of $30,400.00. Following the completion of the transaction, the director now owns 24,033 shares of the company’s stock, valued at approximately $73,060.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 2.26% of the company’s stock.

Hedge Funds Weigh In On Predictive Oncology

Institutional investors and hedge funds have recently modified their holdings of the business. RB Capital Management LLC increased its stake in Predictive Oncology by 161.2% during the 1st quarter. RB Capital Management LLC now owns 416,693 shares of the medical instruments supplier’s stock worth $136,000 after buying an additional 257,193 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Predictive Oncology by 2,582.8% during the second quarter. Renaissance Technologies LLC now owns 405,100 shares of the medical instruments supplier’s stock worth $166,000 after purchasing an additional 390,000 shares in the last quarter. Citadel Advisors LLC acquired a new position in Predictive Oncology during the third quarter worth $65,000. Raymond James & Associates acquired a new position in Predictive Oncology during the third quarter worth $378,000. Finally, Virtu Financial LLC acquired a new stake in shares of Predictive Oncology in the fourth quarter valued at $25,000. Hedge funds and other institutional investors own 6.03% of the company’s stock.

About Predictive Oncology

(Get Free Report)

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.

Featured Stories

Receive News & Ratings for Predictive Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Predictive Oncology and related companies with's FREE daily email newsletter.